XNASRLMD
Market cap11mUSD
Dec 27, Last price
0.38USD
1D
5.74%
1Q
-88.64%
Jan 2017
-65.18%
IPO
-97.45%
Name
Relmada Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
36.67%
Rev. gr., 5y
%
Revenues
0k
Net income
-99m
L-37.09%
CFO
-52m
L-50.23%
Earnings
Mar 17, 2025
Profile
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | 103,702 | 161,249 | 125,705 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (103,702) | (161,249) | (125,705) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (2,659) | 48 | ||||||||
Tax Rate | ||||||||||
NOPAT | (103,702) | (158,590) | (125,753) | |||||||
Net income | (98,792) -37.09% | (157,044) 24.88% | (125,752) 111.50% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 43,432 | 185,311 | ||||||||
BB yield | -42.00% | -46.86% | ||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | (96,324) | (148,323) | (211,910) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (51,659) | (103,802) | (91,873) | |||||||
CAPEX | ||||||||||
Cash from investing activities | 50,453 | 19,734 | (54,118) | |||||||
Cash from financing activities | (98) | 45,020 | 187,939 | |||||||
FCF | (103,702) | (158,590) | (125,752) | |||||||
| Balance | ||||||||||
Cash | 96,324 | 148,323 | 211,910 | |||||||
Long term investments | ||||||||||
Excess cash | 96,324 | 148,323 | 211,910 | |||||||
Stockholders' equity | (560,873) | (462,081) | (305,039) | |||||||
Invested Capital | 646,230 | 602,517 | 513,304 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 30,099 | 29,629 | 17,553 | |||||||
Price | 4.14 18.62% | 3.49 -84.51% | 22.53 -29.75% | |||||||
Market cap | 124,611 20.51% | 103,404 -73.85% | 395,463 -20.92% | |||||||
EV | 28,287 | (44,919) | 183,554 | |||||||
EBITDA | (103,702) | (161,249) | (125,703) | |||||||
EV/EBITDA | 0.28 | |||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||